Therapeutic Bayesian monitoring of sunitinib in two patients with impaired absorption or elimination - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Journal of Clinical Pharmacy and Therapeutics Année : 2021

Therapeutic Bayesian monitoring of sunitinib in two patients with impaired absorption or elimination

Résumé

Sunitinib pharmacokinetics can be influenced by the physio-pathological conditions of individual patients. Therapeutic drug monitoring (TDM) helps to optimize efficacy and reduce the risk of adverse effects. We report on the use of Bayesian analysis to optimize sunitinib blood levels. Case summary: We describe two patients with risk of sunitinib pharmacokinetic variability due to gastrectomy and ongoing haemodialysis, respectively. TDM and Bayesian estimation allowed maintaining their sunitinib pharmacokinetic profiles within the usual limits. What is new and conclusion: Our analysis showed that Bayesian analysis can be successfully applied for real-time TDM to optimize sunitinib blood levels in patients with major comorbidities.

Dates et versions

hal-03632895 , version 1 (06-04-2022)

Identifiants

Citer

Fanny Leenhardt, Marie Viala, Diego Tosi, Emmanuelle Samalin-Scalzi, Alexandre Evrard, et al.. Therapeutic Bayesian monitoring of sunitinib in two patients with impaired absorption or elimination. Journal of Clinical Pharmacy and Therapeutics, 2021, 46 (4), pp.1182-1184. ⟨10.1111/jcpt.13424⟩. ⟨hal-03632895⟩
17 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More